Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
VAXNEUVANCE (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
VAXNEUVANCE
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
pneumococcal purified capsular polysaccharides
Registration type
NCE/NBE
Indication
VAXNEUVANCE (suspension for injection) is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults 18 years of age and older.
VAXNEUVANCE may not prevent disease caused by S. pneumonia serotypes that are not contained in the vaccine.
The use of VAXNEUVANCE should be guided by official recommendations.